Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
Open Access
- 13 May 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective To investigate serum neurofilament light chain (sNfL) as a potential biomarker for disease activity and treatment response in pediatric patients with multiple sclerosis (MS). Methods In this retrospective cohort study, sNfL levels were measured in a pediatric MS cohort (n = 55, follow-up 12–105 months) and in a non-neurologic pediatric control cohort (n = 301) using a high-sensitivity single-molecule array assay. Association of sNfL levels and treatment and clinical and MRI parameters were calculated. Results Untreated patients had higher sNfL levels than controls (median 19.0 vs 4.6 pg/mL; CI [4.732, 6.911]), p < 0.001). sNfL levels were significantly associated with MRI activity (+9.1% per contrast-enhancing lesion, CI [1.045, 1.138], p < 0.001; +0.6% per T2-weighted lesion, CI [1.001, 1.010], p = 0.015). Higher values were associated with a relapse p < 0.001) and a higher Expanded Disability Status Scale score (CI [1.001, 1.240], p = 0.048). In patients treated with interferon beta-1a/b (n = 27), sNfL levels declined from 14.7 to 7.9 pg/mL after 6 ± 2 months (CI [0.339, 0.603], p < 0.001). Patients with insufficient control of clinical or MRI disease activity under treatment with interferon beta-1a/b or glatiramer acetate who switched to fingolimod (n = 18) showed a reduction of sNfL levels from 16.5 to 10.0 pg/mL 6 ± 2 months after switch (CI [0.481, 0.701], p < 0.001). Conclusions sNfL is a useful biomarker for monitoring disease activity and treatment response in pediatric MS. It is most likely helpful to predict disease severity and to guide treatment decisions in patients with pediatric MS. This study provides Class III evidence that sNfL levels are associated with disease activity in pediatric MS.Keywords
This publication has 44 references indexed in Scilit:
- CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disordersJournal of Neuroimmunology, 2014
- Cerebrospinal fluid light and heavy neurofilaments in neuromyelitis opticaNeurochemistry International, 2013
- Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological DiseasesPLOS ONE, 2013
- Cerebrospinal Fluid Brain Injury Biomarkers in Children: A Multicenter StudyPediatric Neurology, 2013
- A Practical Guide to Pediatric Multiple SclerosisNeuropediatrics, 2010
- Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrationsNature Biotechnology, 2010
- Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple SclerosisArchives of Neurology, 2009
- Multiple sclerosisThe Lancet, 2008
- Natural History of Multiple Sclerosis with Childhood OnsetThe New England Journal of Medicine, 2007
- Development of the Blood‐CSF BarrierDevelopmental Medicine and Child Neurology, 1983